Komori
Chordia Therapeutics (190A) · RiskFirst stated

Risk of the renewed spread of COVID-19 affecting business operations

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1257 companies write about · 1269 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.

6 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1283 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「However, if the infection spreads again in the future and the government or other authorities impose restrictions on movement or issue requests to refrain from going out, it may affect the Company's operating results and financial position.」

    Although the infection situation was described as relatively stable, the risk of an impact on operating results from movement restrictions and requests to refrain from going out in the event of a resurgence was disclosed.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of the renewed spread of COVID-19 affecting business operations | Chordia Therapeutics Inc. (190A) | Komori